Sanofi released the aide-mémoire for its second quarter 2026 results on July 1, 2026, providing investors with data to support financial modelling ahead of the full earnings publication. The document, available on the Investors page of sanofi.com, details non-comparable items, foreign currency impact, and share count. The company is scheduled to publish its Q2 2026 results on July 30, 2026.

Key Details

The aide-mémoire is prepared each quarter to assist analysts and investors in modelling the company's financial performance. It focuses on specific adjustments and metrics that may affect comparability.

Publication Schedule

Sanofi will release the complete financial results for the second quarter of 2026 on July 30, 2026. The company is listed on EURONEXT: SAN and NASDAQ: SNY.

Sanofi announced that its therapy Nexviazyme met all primary and secondary endpoints in the Baby-COMET phase 3 study for infantile-onset Pompe disease (IOPD). The study demonstrated that treatment-naïve pediatric participants aged six months and younger remained alive and free of invasive ventilation at 52 weeks of treatment. The company intends to submit this data to support a regulatory application in the US in the second half of 2026.

The Baby-COMET phase 3 study is a single-arm, open-label, international, multicenter trial evaluating Nexviazyme in treatment-naïve pediatric participants with IOPD aged 12 months and younger. Seventeen participants received intravenous Nexviazyme 40 mg/kg every other week. The primary endpoint was the proportion of participants alive and free of invasive ventilation at week 52.

Key Study Findings

Nexviazyme was well tolerated in the study, with a safety profile consistent with the established profile of avalglucosidase alfa. There were no serious treatment-related treatment-emergent adverse events, deaths, or discontinuations reported. Manageable infusion-associated reactions occurred in 29.4% of participants.

Regulatory and Clinical Background

The results will be presented on July 8, 2026, at the 19th International Congress on Neuromuscular Diseases in Florence, Italy. Currently, Nexviazyme is approved in the US for the treatment of late-onset Pompe disease (LOPD) in patients one year of age and older, a status it received in 2021. In Europe, the medicine is available under the name Nexviadyme and received approval for the long-term enzyme replacement therapy of patients with Pompe disease (LOPD and IOPD) in 2022.

Pompe disease is a rare, inherited, progressive neuromuscular disorder caused by a deficiency of the acid alpha-glucosidase (GAA) enzyme. IOPD is the most aggressive variant, manifesting with swift symptom progression during the first months of life. Without therapeutic intervention, IOPD can lead to severe and potentially fatal complications affecting the heart, breathing, and movement. Nexviazyme is designed to help enter cells and improve uptake of the essential GAA enzyme, potentially clearing excess glycogen buildup in muscle cells.